Table 1.
Baseline patient characteristics
| Furosemide (n = 30) | Tolvaptan (n = 30) | P‐value | |
|---|---|---|---|
| Age, years old | 79 ± 11 | 79 ± 11 | 0.93 |
| >75 y/o | 21 (70%) | 20 (67%) | 0.78 |
| Male | 17 (57%) | 13 (43%) | 0.30 |
| BMI, kg/m2 | 24 ± 4.7 | 23 ± 4.8 | 0.64 |
| NYHA IV | 30 (100%) | 30 (100%) | – |
| Current smoking | 4 (13%) | 5 (17%) | 0.72 |
| Hypertension | 26 (87%) | 20 (67%) | 0.07 |
| Diabetes | 15 (50%) | 11 (37%) | 0.30 |
| Dyslipidemia | 18 (60%) | 10 (33%) | 0.038 |
| Hyperuricemia | 13 (43%) | 8 (27%) | 0.18 |
| Coronary artery disease | 15 (50%) | 13 (43%) | 0.60 |
| Prior revascularization | 7 (23%) | 3 (10%) | 0.17 |
| Prior myocardial infarction | 10 (33%) | 8 (27%) | 0.57 |
| Chronic kidney disease* | 19 (63%) | 14 (47%) | 0.19 |
| Atrial fibrillation | 13 (43%) | 11 (37%) | 0.60 |
| LV systolic dysfunction† | 11 (37%) | 9 (30%) | 0.58 |
| FMD, % | 3.4 ± 1.3 | 2.7 ± 1.8 | 0.052 |
| Lab data | |||
| BUN, mg/dL | 23.4 ± 9.6 | 26.0 ± 14.4 | 0.53 |
| Creatinine, mg/dL | 1.03 ± 0.49 | 1.01 ± 0.66 | 0.30 |
| eGFR, mL/min/1.73 m2 | 56.0 ± 27.5 | 63.9 ± 29.7 | 0.24 |
| Sodium, mEq/L | 138 ± 5.1 | 138 ± 6.0 | 0.67 |
| Potassium, mEq/L | 3.9 ± 0.8 | 4.0 ± 0.7 | 0.60 |
| BNP, ng/dL | 721 ± 497 | 1196 ± 901 | 0.15 |
| Albumin, g/dL | 3.2 ± 0.6 | 3.4 ± 0.6 | 0.29 |
| Haemoglobin, g/dL | 12 ± 2.4 | 11 ± 2.2 | 0.15 |
| LDL‐C/HDL‐C | 2.3 ± 1.0 | 2.0 ± 0.9 | 0.32 |
| EPA/AA | 0.38 ± 0.31 | 0.33 ± 0.21 | 1.00 |
BMI: body mass index; EPA/AA: eicosapentaenoic acid/arachidonic acid; FMD: flow mediated dilation; HDL‐C: high density lipoprotein cholesterol; LDL‐C: low density lipoprotein cholesterol; LV: left ventricular; NYHA: New York Heart Association.
Data presented as number (%), or mean ± SD.
*
eGFR < 60 mL/min./1.73 m2.
†
Ejection fraction < 40%.